Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Typically administered as an injection. [10] Victoza: One of Novo Nordisk’s name-brand versions of injectable liraglutide.

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Bengaluru-based Biocon – which is known for its expertise in developing complex biosimilars – has become the first company to ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Eli Lilly's Mounjaro joins list of obesity and diabetes drugs made popular by celebrities who lost weight The latest ...

For Novo Nordisk, a company still rooted in principles ... Leading its current growth is Victoza, a GLP-1 injectable which is used by type 2 diabetes patients, and which now outsells its biggest ...